A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

PHASE4RecruitingINTERVENTIONAL
Enrollment

358

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Biliary Dyspepsia
Interventions
DRUG

CnU capsule 500 mg(250mg 2 capsule)

According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.

DRUG

CnU placebo capsule 500 mg(250mg 2 capsule)

According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.

Trial Locations (6)

Unknown

RECRUITING

Pusan National University Hospital, Busan

RECRUITING

CHA Bundang Medical Center, Gyeonggi-do

RECRUITING

Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do

RECRUITING

Soonchunhyang University Cheonan Hospital, Gyeonggi-do

RECRUITING

Inha University Hospital, Incheon

RECRUITING

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

Myungmoon Pharma. Co. Ltd.

INDUSTRY